01467nas a2200241   4500000000100000008004100001260001200042653002300054653002800077653001200105653002800117653001700145100001200162700001400174700001400188700001500202245012300217856008000340300000800420490000700428520077600435022001401211       2020                            d  c01/202010aantimycobacterials10aemergence of resistance10aleprosy10aprediction of mutations10atuberculosis1 aMunir A1 aVedithi S1 aChaplin A1 aBlundell T00aGenomics, Computational Biology and Drug Discovery for Mycobacterial Infections: Fighting the Emergence of Resistance.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498718/pdf/fgene-11-00965.pdf  a9650 v113 a<p>Tuberculosis (TB) and leprosy are mycobacterial infections caused by  and  respectively. These diseases continue to be endemic in developing countries where the cost of new medicines presents major challenges. The situation is further exacerbated by the emergence of resistance to many front-line antibiotics. A priority now is to design new antimycobacterials that are not only effective in combatting the diseases but are also less likely to give rise to resistance. In both these respects understanding the structure of drug targets in  and  is crucial. In this review we describe structure-guided approaches to understanding the impacts of mutations that give rise to antimycobacterial resistance and the use of this information in the design of new medicines.</p>  a1664-8021